Indofarma Tbk Total Assets
Indofarma Tbk total assets. Based on the latest financial reports, Indofarma Tbk (INAF) holds total assets worth Rp581.56 Billion IDR (≈ $34.08 Million USD) as of September 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Also see Indofarma Tbk market cap and net worth for the company's overall valuation and market capitalisation.
Total Assets of Indofarma Tbk (2000–2024)
Total assets of Indofarma Tbk from 2000 to 2024. This chart illustrates how Indofarma Tbk's total assets have evolved over time, based on quarterly financial data. See Indofarma Tbk (INAF) share price today for real-time trading data and today's change.
Indofarma Tbk - Asset Composition Analysis
Indofarma Tbk Total Assets Breakdown (December 2024)
Indofarma Tbk total assets breakdown as of December 2024. Indofarma Tbk's total assets of Rp581.56 Billion consist of 21.7% current assets and 78.3% non-current assets.
| Asset Category | Amount (IDR) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | Rp0.00 | 1.6% |
| Accounts Receivable | Rp46.92 Billion | 7.6% |
| Inventory | Rp33.33 Billion | 5.4% |
| Property, Plant & Equipment | Rp383.13 Billion | 62.0% |
| Intangible Assets | Rp2.88 Billion | 0.5% |
| Goodwill | Rp0.00 | 0.0% |
Asset Composition Trend (2000–2024)
This chart illustrates how Indofarma Tbk's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. Explore how liquid is Indofarma Tbk's working capital to assess how much short-term liquidity the company maintains relative to its equity base.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Indofarma Tbk's current assets represent 21.7% of total assets in 2024, an increase from 0.0% in 2000.
- Cash Position: Cash and equivalents constituted 1.6% of total assets in 2024, down from 9.6% in 2000.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2000.
- Asset Diversification: The largest asset category is property, plant & equipment at 62.0% of total assets.
Indofarma Tbk Competitors by Total Assets
Key competitors of Indofarma Tbk based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
GALDERMA GROUP AG
NYSE:GALDY
|
USA | $13.39 Billion |
|
Takeda Pharmaceutical Company Limited
F:TKDA
|
Germany | €15.41 Trillion |
|
Galderma Group N
SW:GALD
|
Switzerland | CHF12.88 Billion |
|
Enzymatica publ AB
ST:ENZY
|
Sweden | Skr149.24 Million |
|
Shijiazhuang Yiling Pharmaceutical Co Ltd
SHE:002603
|
China | CN¥13.98 Billion |
|
Hubei Jumpcan Pharmaceutical Co Ltd
SHG:600566
|
China | CN¥17.01 Billion |
|
Kangmei Pharmaceutical Co Ltd
SHG:600518
|
China | CN¥13.68 Billion |
|
Walvax BioTech
SHE:300142
|
China | CN¥10.50 Billion |
Indofarma Tbk - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 0.13 | 0.15 | 1.36 |
| Quick Ratio | 0.10 | 0.07 | 1.18 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | Rp-1.09 Trillion | Rp-1.21 Trillion | Rp297.98 Billion |
Indofarma Tbk - Advanced Valuation Insights
This section examines the relationship between Indofarma Tbk's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 6.53 |
| Latest Market Cap to Assets Ratio | 0.00 |
| Asset Growth Rate (YoY) | -18.6% |
| Total Assets | Rp618.16 Billion |
| Market Capitalization | $22.88 Million USD |
Valuation Analysis
Below Book Valuation: The market values Indofarma Tbk's assets below their book value (0.00x), which may indicate investor concerns about asset quality or future growth.
Significant Asset Reduction: Indofarma Tbk's assets decreased by 18.6% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for Indofarma Tbk (2000–2024)
The table below shows the annual total assets of Indofarma Tbk from 2000 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | Rp618.16 Billion ≈ $36.22 Million |
-18.64% |
| 2023-12-31 | Rp759.83 Billion ≈ $44.52 Million |
-50.47% |
| 2022-12-31 | Rp1.53 Trillion ≈ $89.89 Million |
-23.75% |
| 2021-12-31 | Rp2.01 Trillion ≈ $117.89 Million |
+17.42% |
| 2020-12-31 | Rp1.71 Trillion ≈ $100.39 Million |
+23.80% |
| 2019-12-31 | Rp1.38 Trillion ≈ $81.09 Million |
-4.05% |
| 2018-12-31 | Rp1.44 Trillion ≈ $84.52 Million |
-5.72% |
| 2017-12-31 | Rp1.53 Trillion ≈ $89.64 Million |
+10.73% |
| 2016-12-31 | Rp1.38 Trillion ≈ $80.96 Million |
-9.92% |
| 2015-12-31 | Rp1.53 Trillion ≈ $89.87 Million |
+22.86% |
| 2014-12-31 | Rp1.25 Trillion ≈ $73.15 Million |
-3.57% |
| 2013-12-31 | Rp1.29 Trillion ≈ $75.85 Million |
+8.91% |
| 2012-12-31 | Rp1.19 Trillion ≈ $69.65 Million |
+6.61% |
| 2011-12-31 | Rp1.11 Trillion ≈ $65.33 Million |
+51.90% |
| 2010-12-31 | Rp733.96 Billion ≈ $43.01 Million |
+0.81% |
| 2009-12-31 | Rp728.03 Billion ≈ $42.66 Million |
-24.62% |
| 2008-12-31 | Rp965.81 Billion ≈ $56.59 Million |
-4.32% |
| 2007-12-31 | Rp1.01 Trillion ≈ $59.15 Million |
+46.95% |
| 2006-12-31 | Rp686.94 Billion ≈ $40.25 Million |
+32.40% |
| 2005-12-31 | Rp518.82 Billion ≈ $30.40 Million |
-0.97% |
| 2004-12-31 | Rp523.92 Billion ≈ $30.70 Million |
-17.62% |
| 2003-12-31 | Rp635.96 Billion ≈ $37.26 Million |
-21.49% |
| 2002-12-31 | Rp810.03 Billion ≈ $47.46 Million |
-0.20% |
| 2001-12-31 | Rp811.62 Billion ≈ $47.56 Million |
+50.81% |
| 2000-12-31 | Rp538.17 Billion ≈ $31.53 Million |
-- |
About Indofarma Tbk
PT Indofarma Tbk, together with its subsidiaries, manufactures and sells pharmaceutical products in Indonesia and internationally. The company offers laboratory, pharmaceutical, and health glass equipment; orthopedic and prosthetic equipment; medical and dental equipment; and reparation of Irradiation / X-ray, electromedical and electrotherapy equipment. It also trades in laboratory, pharmaceutic… Read more